Results 11 to 20 of about 193,970 (395)
Biliary tract cancer
European Journal of Surgical OncologyBiliary tract cancers comprise a heterogeneous collection of malignancies usually described as cholangiocarcinoma of the intra- or extrahepatic bile duct, including perihilar cholangiocarcinoma and gallbladder cancer.A review of pertinent parts of the ESSO core curriculum for the UEMS diploma targets (Fellowships exam, EBSQ), based on updated and ...Søreide, Kjetil, Dopazo, Cristina, Berrevoet, Frederik, Carrion-Alvarez, Lucia, Diaz-Nieto, Rafael, Andersson, Bodil, Stättner, Stefan, On behalf of the joint ESSO-EAHPBA-UEMS core curriculum working group, [missing] +7 more +10 more sourcesARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer
Frontiers in Oncology, 2022 BackgroundRecent studies have confirmed that AT-rich interactive domain-containing protein 1A (ARID1A) plays a critical role in tumorigenesis, but its role in gallbladder cancer (GBC) remains unclear.MethodsIn total, 224 patients from Zhongshan Hospital ...Lingxi Nan, Lingxi Nan, Lingxi Nan, Changcheng Wang, Changcheng Wang, Changcheng Wang, Jie Wang, Shulong Zhang, Shulong Zhang, Shulong Zhang, Xiaobo Bo, Xiaobo Bo, Xiaobo Bo, Yueqi Wang, Yueqi Wang, Houbao Liu, Houbao Liu, Houbao Liu, Houbao Liu +18 moredoaj +1 more sourceOuabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells.
PLoS ONE, 2023 Biliary tract cancer is a deadly disease with limited therapeutic options. Ouabain is a well-known inhibitor of the pumping function of Na+/K+-ATPase, though there is evidence that low concentrations of ouabain lead to a reduction of cell viability of ...Christian Mayr, Tobias Kiesslich, Dino Bekric, Marlena Beyreis, Michael Kittl, Celina Ablinger, Elen Neureiter, Martin Pichler, Felix Prinz, Markus Ritter, Daniel Neureiter, Martin Jakab, Heidemarie Dobias +12 moredoaj +2 more sourcesDurvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
Liver international (Print), 2023 The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.M. Rimini, L. Fornaro, S. Lonardi, M. Niger, D. Lavacchi, T. Pressiani, J. Lucchetti, G. Giordano, A. Pretta, E. Tamburini, C. Pirrone, I. Rapposelli, A. Diana, E. Martinelli, I. Garajová, Francesca Simionato, M. Schirripa, V. Formica, C. Vivaldi, E. Caliman, M. Rizzato, Valentina Zanuso, F. Nichetti, L. Angotti, M. Landriscina, M. Scartozzi, M. Ramundo, A. Pastorino, B. Daniele, Noemi Cornara, M. Persano, Eleonora Gusmaroli, Riccardo Cerantola, F. Salani, F. Ratti, L. Aldrighetti, S. Cascinu, L. Rimassa, L. Antonuzzo, A. Casadei‐Gardini +39 moresemanticscholar +1 more sourceTucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Journal of Clinical Oncology, 2023 PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC).Y. Nakamura, N. Mizuno, Y. Sunakawa, J. Canon, M. Galsky, E. Hamilton, H. Hayashi, G. Jerusalem, Seung-Tae Kim, Keun-Wook Lee, L. K. Kankeu Fonkoua, B. Monk, D. Nguyen, Do-Youn Oh, A. Okines, David M. O’Malley, P. Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, C. van Marcke, Evan Y. Yu, R. Groisberg, J. Ramos, Sherry Tan, Thomas E. Stinchcombe, T. Bekaii-Saab +27 moresemanticscholar +1 more sourceCystic Duct Carcinoma: A New Classification System and the Clinicopathological Features of 62 Patients
Frontiers in Oncology, 2021 BackgroundCystic duct carcinoma (CDC) is a rare biliary malignancy with a low incidence and poor prognosis. However, the clinical landscape of the disease has not been clarified and no widely applicable classification system has been developed ...Lingxi Nan, Lingxi Nan, Lingxi Nan, Changcheng Wang, Changcheng Wang, Changcheng Wang, Yajie Dai, Yajie Dai, Yajie Dai, Jie Wang, Jie Wang, Jie Wang, Xiaobo Bo, Xiaobo Bo, Xiaobo Bo, Shulong Zhang, Shulong Zhang, Dexiang Zhang, Dexiang Zhang, Houbao Liu, Houbao Liu, Houbao Liu, Houbao Liu, Yueqi Wang, Yueqi Wang, Yueqi Wang, Yueqi Wang +26 moredoaj +1 more sourceAn Overview of Epigenetic Methylation in Pancreatic Cancer Progression
Frontiers in Oncology, 2022 Over the past decades, the aberrant epigenetic modification, apart from genetic alteration, has emerged as dispensable events mediating the transformation of pancreatic cancer (PC).Yuhao Zhao, Yuhao Zhao, Yuhao Zhao, Mao Yang, Mao Yang, Mao Yang, Shijia Wang, Shijia Wang, Shijia Wang, Sk Jahir Abbas, Sk Jahir Abbas, Junzhe Zhang, Junzhe Zhang, Junzhe Zhang, Yongsheng Li, Yongsheng Li, Yongsheng Li, Rong Shao, Yingbin Liu, Yingbin Liu, Yingbin Liu +20 moredoaj +1 more sourceDevelopment and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit
Frontiers in Oncology, 2021 ObjectivesTo investigate the prognostic significance of the systemic immune-inflammation index (SII) in patients after radical cholecystectomy for gallbladder cancer (GBC) using overall survival (OS) as the primary outcome measure.MethodsBased on data ...Lin Li, Lin Li, Lin Li, Lin Li, Tai Ren, Tai Ren, Tai Ren, Ke Liu, Ke Liu, Ke Liu, Ke Liu, Mao-Lan Li, Mao-Lan Li, Mao-Lan Li, Ya-Jun Geng, Ya-Jun Geng, Ya-Jun Geng, Ya-Jun Geng, Yang Yang, Yang Yang, Yang Yang, Yang Yang, Huai-Feng Li, Huai-Feng Li, Huai-Feng Li, Xue-Chuan Li, Xue-Chuan Li, Xue-Chuan Li, Xue-Chuan Li, Run-Fa Bao, Run-Fa Bao, Run-Fa Bao, Yi-Jun Shu, Yi-Jun Shu, Yi-Jun Shu, Hao Weng, Hao Weng, Hao Weng, Wei Gong, Wei Gong, Wei Gong, Wan Yee Lau, Xiang-Song Wu, Xiang-Song Wu, Xiang-Song Wu, Ying-Bin Liu, Ying-Bin Liu, Ying-Bin Liu, Ying-Bin Liu +48 moredoaj +1 more sourceImmunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer. [PDF]
Cancer Immunol ImmunotherChen X, Zhou Z, Li S, Yu G, Feng S, Zhou Z, Sun B, Wang S, Liu K, Li C, Piao M, Wang M, Zhang Y, Li H, Zhu C, Zhu Z, Zhao H. +16 moreeuropepmc +3 more sources
